PL1909845T3 - Amid N,N-bis-(2-hydroksyetylo)glyciny jako łącznik w prolekach sprzężonych z polimerem - Google Patents

Amid N,N-bis-(2-hydroksyetylo)glyciny jako łącznik w prolekach sprzężonych z polimerem

Info

Publication number
PL1909845T3
PL1909845T3 PL06777407T PL06777407T PL1909845T3 PL 1909845 T3 PL1909845 T3 PL 1909845T3 PL 06777407 T PL06777407 T PL 06777407T PL 06777407 T PL06777407 T PL 06777407T PL 1909845 T3 PL1909845 T3 PL 1909845T3
Authority
PL
Poland
Prior art keywords
linker
hydroxyethyl
bis
polymer conjugated
glycine amide
Prior art date
Application number
PL06777407T
Other languages
English (en)
Inventor
Dirk Vetter
Harald Rau
Thomas Wegge
Ulrich Hersel
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of PL1909845T3 publication Critical patent/PL1909845T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06777407T 2005-06-22 2006-06-21 Amid N,N-bis-(2-hydroksyetylo)glyciny jako łącznik w prolekach sprzężonych z polimerem PL1909845T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0512705A GB2427360A (en) 2005-06-22 2005-06-22 Aliphatic prodrug linker
EP06777407A EP1909845B1 (en) 2005-06-22 2006-06-21 N,n-bis-(2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs
PCT/EP2006/063418 WO2006136586A2 (en) 2005-06-22 2006-06-21 N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs

Publications (1)

Publication Number Publication Date
PL1909845T3 true PL1909845T3 (pl) 2013-01-31

Family

ID=34855956

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06777407T PL1909845T3 (pl) 2005-06-22 2006-06-21 Amid N,N-bis-(2-hydroksyetylo)glyciny jako łącznik w prolekach sprzężonych z polimerem

Country Status (14)

Country Link
US (1) US8980242B2 (pl)
EP (1) EP1909845B1 (pl)
JP (1) JP5121068B2 (pl)
CN (1) CN101242859B (pl)
AU (1) AU2006260914B2 (pl)
BR (1) BRPI0612536A2 (pl)
CA (1) CA2613208C (pl)
CY (1) CY1113204T1 (pl)
ES (1) ES2390816T3 (pl)
GB (1) GB2427360A (pl)
MX (1) MX2007016547A (pl)
PL (1) PL1909845T3 (pl)
SI (1) SI1909845T1 (pl)
WO (1) WO2006136586A2 (pl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811572B2 (en) 2005-08-24 2010-10-12 Immunogen, Inc. Process for preparing purified drug conjugates
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
WO2008148839A2 (en) * 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
EP2067494A1 (en) 2007-12-04 2009-06-10 Charité-Universitätsmedizin Berlin Sheet or tubular structure consisting of elastic biocompatible material and its use
LT2237799T (lt) * 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
CA3004716C (en) 2008-04-29 2022-04-12 Ascendis Pharma Endocrinology Division A/S Pegylated recombinant human growth hormone compounds
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
BRPI0921640A2 (pt) 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
CN102413843A (zh) 2009-03-05 2012-04-11 阿森迪斯药物股份有限公司 干扰素α载体前药
EP2432489B1 (en) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
JP5784592B2 (ja) 2009-06-03 2015-09-24 イミュノジェン・インコーポレーテッド 抱合方法
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
KR20120089843A (ko) 2009-07-31 2012-08-14 사노피-아벤티스 도이칠란트 게엠베하 인슐린 링커 접합체를 포함한 프로드럭
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010311421B2 (en) 2009-10-29 2014-11-20 Ascendis Pharma A/S Sterilization of biodegradable hydrogels
KR20120103606A (ko) 2009-11-04 2012-09-19 얀센 파마슈티카 엔.브이. 스트레스코핀-유사 펩타이드를 이용해 심부전을 치료하는 방법
EP2512450B1 (en) 2009-12-15 2018-02-07 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
EA033468B1 (ru) 2011-03-29 2019-10-31 Immunogen Inc Способы получения конъюгата "антитело-майтансиноид"
CA2837588A1 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
US20140323402A1 (en) 2011-08-12 2014-10-30 Ascendis Phama A/S Protein Carrier-Linked Prodrugs
EP2741779A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
HK1198628A1 (en) 2011-08-12 2015-05-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
MX2014003993A (es) 2011-10-12 2014-08-08 Ascendis Pharma Ophthalmology Division As Prevencion y tratamiento de condiciones oculares.
JOP20190001B1 (ar) 2011-11-03 2022-03-15 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
BR112014010806A2 (pt) 2011-11-03 2017-05-02 Bayer Ip Gmbh ligadores à base de tirosina para a ligação reversível de peptídeos
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CN108383902A (zh) * 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
EP2904089A4 (en) 2012-10-04 2016-05-25 Immunogen Inc USE OF A PVDF MEMBRANE FOR PURIFYING CELL BINDING AGENT-CYTOTOXIC AGENT CONJUGATES
MY186106A (en) 2012-10-11 2021-06-22 Ascendis Pharma As Diagnosis, prevention and treatment of diseases of the joint
JP6271566B2 (ja) 2012-10-11 2018-01-31 アセンディス ファーマ エー／エス ヒドロゲルプロドラッグ
DK2906246T3 (da) 2012-10-11 2023-09-04 Ascendis Pharma Ophthalmology Div A/S VEGF-neutraliserende prodrugs omfattende ranibizumab til behandling af okulære tilstande, der er kendetegnet ved okulær neovaskularisering
US11116849B2 (en) 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
CA2925190C (en) 2013-10-08 2021-10-12 Ascendis Pharma A/S Protecting group comprising a purification tag
CA2929201A1 (en) 2013-11-11 2015-05-14 Ascendis Pharma Relaxin Division A/S Relaxin prodrugs
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
ES2993327T3 (en) 2014-08-06 2024-12-27 Ascendis Pharma As Prodrugs comprising an aminoalkyl glycine linker
CN107001440A (zh) 2014-09-26 2017-08-01 拜耳制药股份公司 稳定化的肾上腺髓质素衍生物及其用途
US10265413B2 (en) 2014-11-05 2019-04-23 University Of The Sciences In Philadelphia High molecular weight biodegradable gelatin-doxorubicin conjugate
KR102608645B1 (ko) 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그
EP4732848A3 (en) 2014-11-21 2026-07-29 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
WO2016196124A2 (en) 2015-05-29 2016-12-08 Ascendis Pharma Inc. Prodrugs comprising a pyroglutamate linker
AU2017205693B2 (en) 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
CA3008015A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
US10835578B2 (en) 2016-01-08 2020-11-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
KR102518217B1 (ko) 2016-01-08 2023-04-04 아센디스 파마 그로우쓰 디스오더스 에이/에스 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제
EP4710947A3 (en) 2016-01-08 2026-06-17 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
JP6968802B2 (ja) 2016-01-08 2021-11-17 アセンディス ファーマ グロース ディスオーダーズ エー／エス 環部分にキャリア結合を有するｃｎｐプロドラッグ
SI3423103T1 (sl) 2016-03-01 2024-12-31 Ascendis Pharma Bone Diseases A/S Predzdravila PTH
CA3016814A1 (en) 2016-03-16 2017-09-21 Prolynx Llc Extended release conjugates of exenatide analogs
AU2017295938C1 (en) 2016-07-13 2021-10-07 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
CA3034895A1 (en) 2016-08-26 2018-03-01 Exciva Ug (Haftungsbeschrankt) Compositions and methods thereof
JP7039574B2 (ja) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー／エス 放出制御ｐｔｈ化合物の漸増用量設定
KR102611820B1 (ko) 2016-09-29 2023-12-07 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
HUE063235T2 (hu) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US12150996B2 (en) * 2017-11-17 2024-11-26 Centre National De La Recherche Scientifique Polymeric prodrugs and subcutaneous and/or intramuscular administration thereof
CA3099620A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
CA3114056A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
EP3856256A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
CA3114272A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
SG11202105835YA (en) 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists
SG11202104966XA (en) 2019-01-04 2021-06-29 Ascendis Pharma Oncology Div A/S Sustained local drug levels for innate immune agonists
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
AU2020205029A1 (en) 2019-01-04 2021-06-24 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
AU2020221491B2 (en) 2019-02-11 2025-02-27 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
JP7524206B2 (ja) 2019-03-04 2024-07-29 アセンディス ファーマ エンドクライノロジー ディヴィジョン エー／エス １日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
WO2020219943A1 (en) 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
CA3143278A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
TW202114738A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 抗ctla4結合物
CN115003345B (zh) * 2019-11-30 2026-01-27 智能反应堆服务有限公司 用于医疗器械的涂层
JP2023510790A (ja) 2020-01-13 2023-03-15 アセンディス ファーマ ボーン ディジージズ エー／エス 副甲状腺機能低下症の治療
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
IL301411A (en) 2020-09-28 2023-05-01 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism
CN112251484B (zh) * 2020-10-26 2022-05-24 江南大学 一种脂肪酶催化制备甘氨酸寡肽-聚乙二醇共聚物的方法
AU2022350937A1 (en) 2021-09-22 2024-03-21 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
JP2024546134A (ja) 2021-12-13 2024-12-17 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｔｌｒ７／８アゴニストを用いたがん治療
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2023276829A1 (en) 2022-05-23 2024-10-31 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
IL323019A (en) 2023-03-06 2025-10-01 Ascendis Pharma As Drug compounds with an albumin-binding moiety
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
EP4676535A1 (en) 2023-03-06 2026-01-14 Ascendis Pharma A/S Multi-albumin binding compounds
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
EP4773987A1 (en) 2023-09-04 2026-07-15 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
CN117959250A (zh) * 2024-03-27 2024-05-03 长春生物制品研究所有限责任公司 一种重组人白细胞介素-1受体拮抗剂注射液
WO2026013136A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding compounds
WO2026013138A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Compounds with improved albumin-binding
WO2026013135A1 (en) 2024-07-10 2026-01-15 Ascendis Pharma A/S Albumin-binding reagents
CN119139539B (zh) * 2024-11-19 2025-01-10 广东海洋大学 一种抗菌水凝胶及其制备方法与应用
WO2026139471A1 (en) 2024-12-23 2026-07-02 Ascendis Pharma Growth Disorders A/S Use of cnp or cnp conjugates such as navepegritide to treat leg curvature in patients with skeletal dysplasia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
MXPA04005611A (es) * 2001-12-11 2005-04-19 Cellgate Inc Reactivos y conjugados de transporte de guanidinio.
US20040005641A1 (en) 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US20050271615A1 (en) 2002-08-30 2005-12-08 Doron Shabat Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
US20080125363A1 (en) * 2004-12-14 2008-05-29 Enzon Pharmaceuticals Inc. Polymer-Linked Pseudomonas Exotoxin Immunotoxin

Also Published As

Publication number Publication date
CA2613208A1 (en) 2006-12-28
GB0512705D0 (en) 2005-07-27
BRPI0612536A2 (pt) 2010-11-23
EP1909845B1 (en) 2012-08-15
ES2390816T3 (es) 2012-11-16
US8980242B2 (en) 2015-03-17
MX2007016547A (es) 2008-02-21
CA2613208C (en) 2014-01-21
US20100291021A1 (en) 2010-11-18
GB2427360A (en) 2006-12-27
CN101242859A (zh) 2008-08-13
SI1909845T1 (sl) 2012-11-30
CN101242859B (zh) 2013-04-03
WO2006136586A3 (en) 2007-07-26
AU2006260914B2 (en) 2011-04-14
CY1113204T1 (el) 2016-04-13
JP5121068B2 (ja) 2013-01-16
JP2008543916A (ja) 2008-12-04
EP1909845A2 (en) 2008-04-16
AU2006260914A1 (en) 2006-12-28
WO2006136586A2 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
SI1909845T1 (sl) N N bis hidroksietil glicin amid kot linker vpolimerno konjugiranih predzdravilih
DK1931250T3 (da) Elektrodebundt
DE602005026254D1 (de) Geschalteter Reluktanzgenerator
AT501146B8 (de) Arbeitstisch
ATE500244T1 (de) 1,5-substituierte indol-2-yl amidderivative
PT1924246E (pt) Formulação sachê para polímeros com funcionalidade amina
EP2108368A4 (en) POLY (GLUTAMIC ACID) ARZNEI CONJUGATE WITH AN AMINO ACID AS LEFT
ITMO20050009A1 (it) Apparato di serraggio.
EP1912680A4 (en) HER-2 PEPTIDE
DE602006005955D1 (de) Schraubzwinge
EP1858914A4 (en) NETWORKS OF PEPTIDES
EP2119702A4 (en) amide derivative
DE602006004661D1 (de) Gestreckte Polyamidfilme
DK1968623T3 (da) Bacteriocin-inducer-peptider
NL1031705A1 (nl) Aminozuurderivaten.
EP2181984A4 (en) N- (alpha-MERCAPTOPROPIONYL) GLYCINE OPTICALLY ACTIVE
ITRE20050027U1 (it) Spaccalegna perfezionato
ITRE20050028U1 (it) Spaccalegna perfezionato
UA13585S (uk) Затискач
EP1907843A4 (en) Uniformly conjugated serine hydrolases
DE502005011235D1 (de) Prüfstand
ES1061711Y (es) Dispositivo autocentrable para pinza.
NO20050080D0 (no) Bronnramme/manifold arrangement
ES1061478Y (es) Peana para sujecion de sombrillas perfeccionada
ES1061653Y (es) Atril perfeccionado para vehiculos